At PCR, How Big is Small?

With each passing year, clinical trials reaffirm the efficacy of drug-eluting stents in reducing or eliminating restenosis. But the devices' success have raised concerns of a different sort: safety, and specifically, the risk of subacute and late stent thrombosis.

When the first clinical trials on drug-eluting stents were reported, the results were breath-taking. The earliest trials, FIM and RAVEL, showed zero-percent restenosis, and though few of the follow-up trials, which have explored more difficult patient sub-groups such as diabetics and patients with long and bifurcated lesions, have demonstrated such absolute results, they've continued to affirm the radical efficacy of drug-eluting stents (DES). But even as DES' efficacy is proven in trial after trial, a new concern has surfaced: do the revolutionary devices cure one large problem, restenosis, only to cause another, and potentially more deadly one, thrombosis? By all accounts, the risk of thrombosis is small. But it's one that interventionalists take seriously, and at this year's Paris Course on Revascularization (PCR) meeting, physicians in a number of sessions debated intently how seriously stent-induced thrombosis should be taken and whether the incidence warrants increased caution in the use of drug-eluting stents.

Even physicians who reported relatively little incidence of subacute (SAT) and late stent thrombosis (LST) seem to be worrying about...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.   

Shape Our Content: Take The Reader Survey

 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

In Partnership with Cerba Research

Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.

More from In Vivo

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By 

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By 

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By 

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.